Gossamer Bio GOSS 深 沪
已收盘 07-02 16:00:00 美东时间
0.1732
+0.006
+3.28%
华盛通- 最 高0.1775
- 今 开0.169
- 成交量 1652.61万股
- 最 低 0.164
- 昨 收 0.1677
- 总市值 8466.83万
- 52周最高 3.87
- 市盈率 静 --
- 换手率 3.38%
- 52周最低 0.14
- 委 比 96.12%
- 总股本 4.89亿
- 历史最高 27.15
- 量 比 0.94
- 振 幅 8.05%
- 历史最低 0.14
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gossamer Bio确定2030年可转换票据转换率及认股权证行权价
Gossamer Bio（纳斯达克代码：GOSS）宣布，已确定其2030年到期的7.50%优先担保可转换票据的初始转换率，以及相关认股权证的初始行权价格。...
07-01 21:47
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $5 to $2.
06-26 00:32
Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today ...
06-17 20:15
快讯 | Gossamer Bio, Inc.宣布就现有可转换票据的交换要约及同意征求的最终收购结果
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consen...
06-17 20:00
快讯 | Gossamer Bio - $1.811亿 的现有可转换票据已于2026年6月2日提交要约收购
Gossamer Bio - $181.1 Mln of Existing Convertible Notes Tendered as of June 2, ...
06-17 20:00
快讯 | Gossamer Bio——取消现有票据中大部分限制性契约和违约事件
Gossamer Bio - Eliminates Most Restrictive Covenants and Events of Default on E...
06-17 20:00
Harbour BioMed appoints Luisa Salter-Cid as scientific advisor
Harbour BioMed appoints Luisa Salter-Cid as scientific advisor HBM Holdings named immunology and immuno-oncology executive Luisa Salter-Cid as scientific advisor on June 10, 2026. Salter-Cid is a venture partner at Osage University Partners. She previously served as chief scientific officer of Pione
06-11 09:52
Gossamer Bio shareholders reaffirm board and governance structure
Gossamer Bio ( ($GOSS) ) has shared an announcement. At its 2024 annual meeting...
06-05 18:46
